Retinoblastoma Loss Modulates DNA Damage Response Favoring Tumor Progression

Marcos Seoane¹, Pablo Iglesias¹, Teresa Gonzalez², Fernando Dominguez², Maximo Fraga³, Carlos Aliste³, Jeronimo Forteza³, Jose A. Costoya¹

¹ Molecular Oncology Lab, Departamento de Fisioloxía, Facultade de Medicina, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, ² Fundación Galega de Medicina Xenomica, Servicio Galego de Saude, Santiago de Compostela, Spain, ³ Departamento de Anatomia Patoloxica e Ciencias Forenses, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

Abstract

Senescence is one of the main barriers against tumor progression. Oncogenic signals in primary cells result in oncogene-induced senescence (OIS), crucial for protection against cancer development. It has been described in premalignant lesions that OIS requires DNA damage response (DDR) activation, safeguard of the integrity of the genome. Here we demonstrate how the cellular mechanisms involved in oncogenic transformation in a model of glioma uncouple OIS and DDR. We use this tumor type as a paradigm of oncogenic transformation. In human gliomas most of the genetic alterations that have been previously identified result in abnormal activation of cell growth signaling pathways and deregulation of cell cycle, features recapitulated in our model by oncogenic Ras expression and retinoblastoma (Rb) inactivation respectively. In this scenario, the absence of pRb confers a proliferative advantage and activates DDR to a greater extent in a DNA lesion-independent fashion than cells that express only HRasV12. Moreover, Rb loss inactivates the stress kinase DDR-associated p38MAPK by specific Wip1-dependent dephosphorylation. Thus, Rb loss acts as a switch mediating the transition between premalignant lesions and cancer through DDR modulation. These findings may have important implications for the understanding of the biology of gliomas and anticipate a new target, Wip1 phosphatase, for novel therapeutic strategies.

Introduction

Cell proliferation is dependent on the appropriate transmission of growth signals from the cell membrane to the nucleus. Ras family proteins function as a membrane-associated biologic switch that relays signals from ligand-stimulated receptors to cytoplasmatic downstream effectors proteins like phosphoinositide 3-kinase (PI3K) and Raf-MEK1/2. These protein-kinases are responsible of phosphorylation of transcription factors, which in last instance contribute to proliferation, differentiation and cell survival. The importance of the Ras/Raf/MEK/ERK pathway in growth control is further supported by the fact that hyperactivation of this pathway is usually found associated with many human tumors such as gliomas.

Gliomas are the most common primary tumors in the brain and are divided into four clinical grades on the basis of their histology and prognosis [1]. Several gene expression alterations and chromosomal abnormalities are commonly found in gliomas, and in some cases these mutations correlate with clinical grade. One common alteration in gliomas of all grades is the overproduction of growth factors such as FGF2, EGF and PDGF19, and their receptors. Interestingly, although mutations in Ras are not found in gliomas, overexpression and/or gain-of-function mutations in several growth factor receptors increase Ras activity [2–4], activating downstream effectors like Raf/MEK/ERK and PI3K/AKT pathways [5]. Indeed, several mouse models of glioma have causally implicated activated HRas and KRas in glioma formation [6–8].

Deregulation of signal transduction pathways mutations is found both in low- and high-grade gliomas, whereas other mutations are predominantly found in one or another group of gliomas. Thus, nearly all WHO grade III and IV (GBM) show a disruption of cell cycle due to alterations in one out of three genetic loci governing G1 arrest such as: CDK4, INK4a–ARF or Rb. Over half of high-grade human gliomas lack a functional INK4a–ARF locus [9,10] and hence can produce neither p16INK4a nor p15ARF, the two proteins encoded by this locus [11]. Most of the remaining gliomas either demonstrate a great amplification of the CDK4 locus or lack the Rb gene [12–14] conjointly, in some cases, with p53 alterations [15].

Curiously, in human and rodent cells, oncogenic signals result in a permanent G1 arrest known as OIS [16,17]. Although diverse stimuli can induce a senescence response, they appear to converge on p16INK4a/pRb and/or p15ARF/p53 pathways that establish and maintain the senescence growth arrest. In fact, increased expression levels of p53, p19ARF and p16INK4a have been found in murine cells undergoing OIS, as well as in some human premalignant neoplastic lesions [18–21].
Several oncogenes like Ras induce DNA replication stress, which leads to activation of the DNA damage response (DDR). This response includes phosphorylation of kinases such as ATM and Chk2, histone H2AX and p53 [19,20,22], which ultimately force the cell to undergo oncogene-induced senescence (OIS). Like apoptosis, OIS is a tumor-suppressing defense mechanism that must be compromised for tumorigenesis to occur.

In the same way, recent studies have revealed a major role of the p38MAPK pathway in OIS caused by oncogenic Ras [23,24]. Although, part of the tumor-suppressive function of p38MAPK is attributed to its ability to mediate apoptosis as a result of ROS accumulation induced by activated oncogenes [25].

Here, we have developed a new model for gliomagenesis in hopes of understanding these patterns and discerning the contributions made to tumor formation. Similar approaches have been used before by other groups to recreate the behavior of glioma cells introducing in astrocytes some of the genetic lesions mentioned above [26–28]. We demonstrate that astrocytes are resistant to Ras-induced senescence in presence of high levels of ROS and DNA damage despite DDR activation. Moreover, in this context, loss of Rb locus favors the progression of low-grade gliomas to higher-grade tumors by conferring a double selective advantage to the tumor. First, deregulation of the pRb-E2F1 pathway is able to stimulate DDR activation through activation of ATM to phosphorylate p53 without increasing DNA double-strand breaks (DSBs) or ROS production [29]. This preferential activation of the DNA damage response increases DNA repair capacity that is essential for tumor cell survival. Finally, loss of Rb locus negatively regulates p38MAPK phosphorylation. Down-regulation of the p38MAPK signaling pathway is achieved through E2F-induced up-regulation of Wip1, a specific phosphatase that dephosphorylates and inactivates p38MAPK [30], also favoring the progression to astrocyte transformation.

Results

Considering that upregulation of growth factor signaling pathways and the loss of cell cycle regulators are common features in glioblastoma multiforme [31], we address the role of HRasV12 and/or Rb loss in conditional Rb murine astrocytes to explain the tumor initiation and maintenance. To this purpose, conditional Rb mutant mouse astrocytes were infected by retrovirus encoding mutant Ras allele (HRasV12) and the recombinase Cre that targets the loxP sequences flanking exon 19 of the Rb gene [32]. Thus, we managed to mimic the characteristic upregulation of EGFR and FGFR signaling pathways by introducing a constitutively activated isoform of Ras, and the cell cycle deregulation by genetically inactivating the pocket protein Rb.

However, previous studies have reported that primary MEFs enter senescence upon oncogenic stress induced by ectopic expression of the oncogenic HRasV12 [17,33]. Also, it has been reported that the absence of pRb enables Ras activation modulating differentiation in MEFs [34]. Accordingly, we carried out several infection assays on MEFs where we observed that all experimental groups enter senescence after HRasV12 expression (data not shown), as others reported.

Unexpectedly, we observed that the astrocytes infected with PIG-Cre/pBABE-HRasV12 retroviral vector (hereafter cRb-S/−/RasV12) showed after one week an increased proliferation rate when compared with the remaining groups. Astrocytes infected with PIG-Cre/pBABE (hereafter cRbloxF/loxP) and PIG/pBABE (hereafter cRbLoxF/loxP/RasV12) were used as control groups. To our surprise, astrocytes infected with PIG/pBABE-HRasV12 (hereafter cRbLoxF/loxP/RasV12) also displayed a dramatic increment when compared with the control group, although at a less extent than cRbLoxF/loxP/RasV12 astrocytes. Proliferative differences between astrocytic populations can be easily spotted in Figure 1A. To further support these data, we carried out a BrdU incorporation assay on all of the experimental groups, as shown in Figures 1B and 1C, that confirmed our initial observation.

These data is compatible with the observation that both cRbLoxF/loxP/RasV12 and cRb−/−/RasV12 groups did not show SA-β-Gal positive staining (Figure 1E), either in the presence or absence of pRb. Thus, our findings suggest that oncogenic Ras alone, regardless of pRb status, is sufficient to increase proliferation in astrocytes and at the same time, circumvent the oncogene-induced senescence seen in MEFs. Furthermore, Rb loss cooperates with oncogenic Ras enhancing the growth rate but without inducing senescence (Figures 1D and 1E) or apoptosis in astrocytes (data not shown), as others previously reported in other cellular systems [35].

Unlike normal primary astrocytes, flattened and non-refractile cells, Ras-expressing astrocytes showed noticeable morphological changes and loss of contact inhibition, and although flat cells were also present, the population was heterogeneous and large displaying at the same time a refractile cytoplasm with thin and long projections (Figure 2A). It is also revealing the fact that although Rb-deficient astrocytes displayed a marked proliferative increase its morphology did not appear significantly changed. On the contrary, Ras-expressing astrocytes seemed to undergo dramatic morphological alterations suggesting a transformed phenotype. We then wondered if these astrocytes would also exhibit foci growth, which is a characteristic feature of transformed cells. As Figure 2B shows, HRasV12 seems to induce foci growth as seen in cRbLoxF/loxP/RasV12 and cRb−/−/RasV12 cells, whereas the remaining groups do not show significant foci formation.

To further support the hypothesis concerning the transformed status of these cells, we injected subcutaneously all the experimental groups in SCID mice. cRbLoxF/loxP/RasV12 astrocytes formed detectable tumors (N = 2/13; p = NS) within 8–15 weeks whereas tumors formed by cRb−/−/RasV12 (N = 13/13; p < 0.0001) appeared in-between the first and second week. No tumors were observed in mice injected with cRbLoxF/loxP (N = 0/11) or cRb−/− (N = 0/7) astrocytes (Figures 2C and 2D). Together, our data suggest that HRasV12 and Rb loss promote the transformation of those cells. However, HRasV12 alone is also able to induce cellular growth in a minor extent and with a long latency, suggesting that in this case a second oncogenic event is needed to trigger tumorigenesis.

Histopathological examinations of the tumors generated from cRb−/−/RasV12 cells showed a high degree of vascularization (Figure 2E) and necrotic regions surrounding the tumoral core, caused by the chaotic cell growth observed in the tumoral morphology resembling to those observed in human GBMs. However, tumors observed in mice injected with cRbLoxF/loxP/RasV12 astrocytes bore a strong similarity with human low-grade gliomas, showing moderate cellularity and few mitoses (Figure 2E). Therefore, although in other cell systems like MEFs, [17,21,33] it seems to be indispensable the loss of at least one tumor suppressor to make cells more susceptible to Ras-induced hyper-replication effects. In primary astrocytes, HRasV12 oncogenic activity alone is sufficient to unleash cellular hyper-proliferation but not in vitro tumor formation. Then, Rb inactivation, besides enhancing cellular growth in HRasV12-expressing astrocytes (Figures 1A, 1B and 1C), also confers a higher aggressiveness to the tumor (Figures 2C and 2D).

As we previously described, although astrocytes harboring HRasV12 did not enter senescence we wanted to confirm whether
DNA damage provoked by DNA replication stress, and usually associated with oncogene-induced senescence, was present. On the other hand, HRasV12 is also known to cause an increase in reactive oxygen species (ROS) production [36] as a result of replication stress. ROS has been traditionally considered as a toxic by-product of cellular metabolism, but it has been appreciated that they are actively involved in oncogenic signaling in cellular transformation and cancer. Increased intracellular levels of ROS have also been reported to mediate some biological effects of oncogenic HRasV12, such as the onset of premature senescence in primary cells, the generation of genomic instability [37], and malignant transformation [38]. Furthermore, high levels of ROS have been detected in several human cancer cell lines as well as in human tumors from different tissues. Taken together these reports, we wanted to analyze in astrocytes the relationship between oxidative stress and glioma. We observed similar oncogene-induced ROS accumula-

Figure 1. Mouse astrocytes are defective for HRasv12-induced cell cycle arrest. a, Growth curve analysis of early-passage cRbloxP/loxP conditional astrocytes co-infected with PIG/pBABE (vector), PIG/pBABE-HRasV12, PIG-Cre/pBABE and PIG-Cre/pBABE-HRasV12 retroviral vectors. After infection, cells were plated in triplicate and the cells were fixed on the indicated days for subsequent staining with crystal violet. Each time point represents the mean±s.d. of total cumulative cell number from at least three independent experiments. b, Measurement of the proliferation of astrocytes by BrdU incorporation assay (panel c). c, Cells were labeled with BrdU for 5 h on day 5 after puromycin selection. d, Senescence assays in cRbloxP/loxP and cRb1/2. The y-axis represents the percentage of SA-β-galactosidase-positive cells (mean and s.d.) from at least three independent experiments. e, A representative result of three independent experiments is shown. Photographs are at the same magnification.

doi:10.1371/journal.pone.0003632.g001
tion in cRb\textsuperscript{loxP/loxP}/Ras\textsuperscript{V12} and cRb\textsuperscript{2/2}/Ras\textsuperscript{V12} astrocytes, but not in those that had lost only Rb (Figure 3A). Likewise, we found signs of chromosomal instability (Figure 3B–D) in the groups that expressed HRas\textsuperscript{V12} and displayed ROS accumulation. One of the most remarkable features of cRb\textsuperscript{loxP/loxP}/Ras\textsuperscript{V12} and cRb\textsuperscript{2/2}/Ras\textsuperscript{V12} astrocytes is the abundance of centromeric instability manifested as centromere fragments (CF) (Figure 3D and Figure S1). We also found Robertsonian centromere fusion (Rob) in cRb\textsuperscript{loxP/loxP}/Ras\textsuperscript{V12} and cRb\textsuperscript{2/2}/Ras\textsuperscript{V12} astrocytes but not in cRb\textsuperscript{2/2} and wildtype astrocytes (Figure S1). In addition, there were numerical chromosome abnormalities in the experimental groups that expressed oncogenic Ras. These astrocytes presented >80 chromosomes per cell, doubling the chromosome number found in control cells (Figure 3B and 3C). Hence, these numerical and structural chromosome abnormalities show that activated Ras is sufficient to induce chromosomal instability in the absence of other signals, suggesting that Ras-induced chromosomal instability arises as consequence of ROS accumulation and DNA replication.

Figure 2. HRas\textsuperscript{V12} in the absence of Rb induces malignant transformation both in vitro and in vivo. a, Ability to form foci, representative pictures of wells stained with crystal violet (day 7). b, Representative pictures of wells stained on the indicated days of culture showing the morphological change observed in each group are also shown. c, Tumor-free survival curve (Kaplan-Meier plot) for tumor formation in SCID mice. Tumor was found in cRb\textsuperscript{2/2}/Ras\textsuperscript{V12} cohort (P<0.0001) d, Photographs of SCID mice after subcutaneous injection of cRb\textsuperscript{loxP/loxP}/Ras\textsuperscript{V12} and cRb\textsuperscript{2/2}/Ras\textsuperscript{V12} astrocytes at eleven and two weeks respectively. Actual sizes of tumors after biopsy. e, Low-grade gliomas (cRb\textsuperscript{loxP/loxP}/Ras\textsuperscript{V12}; H&E, upper left) showed a rather monomorphic appearance, with polygonal or rounded cell shape and smaller rounded nuclei without prominent nucleoli. Note the absence of mitosis and necrosis. In contrast, high-grade gliomas (cRb\textsuperscript{2/2}/Ras\textsuperscript{V12}; H&E, lower left) displayed cellular pleomorphism, with large, fusiform and irregular nuclei that frequently exhibit mitotic figures (upper left corner) and necrotic foci (lower right corner). Co-expression of EGFP permits the visualization of the previously modified astrocytes.

doi:10.1371/journal.pone.0003632.g002
stress. In addition, there is not a significant difference between cRb\(^{loxP/loxP}\)/Ras\(^{V12}\) and cRb\(^{-/-}\)/Ras\(^{V12}\) astrocytes implying that the absence of pRb has not effect on DNA lesions, either quantitative or qualitative.

These observations suggest that the presence of DNA lesions may trigger DDR activation. Although the mechanisms that generate DNA damage put in place by different oncogenic events are unclear presently, Ras activation induces not only ROS-induced DNA damage but also re-replication, an event known to cause DDR activation [21]. DDR is likely to be related to premalignant neoplastic lesions in human [18,39–41], and has been linked to increased expression levels of p16\(^{INK4A}\) and p19\(^{ARF}\) induced DNA damage but also re-replication, an event known to generate DNA damage put in place by different oncogenic events may trigger DDR activation. Although the mechanisms that quantitative or qualitative.

Wip1 [50]. Wip1 is a serine/threonine phosphatase of the type 2C protein phosphatase family (PP2C). This family of phosphatases, highly conserved in eukaryotes, is frequently associated with regulation of cellular stress responses [31]. An important amount of data published in the last years suggests that Wip1 is an oncogene. This phosphatase cooperates with other oncogenes to transform murine embryonic fibroblasts [52]. Recently, it has been reported that E2F-1 down-regulates p38MAPK signaling pathway through E2F-induced up-regulation of Wip1 [30]. Accordingly, in our experimental setting Rb-null glial cells showed increased levels of this phosphatase, which explains the down-regulation of phosphorylated p38MAPK (Figure 4B).

To further validate our observations, human low- and high-grade glioma sections were labeled for this marker. High levels of pWip1 expression correlate with high-grade tumors (Figure 4C).

Also, to test our hypothesis regarding the Ras-pRb loss cooperation mediated by Wip1, all experimental groups were treated with two chemical inhibitors upon infection, CCT007093 [57] and Arsenic Trioxide [58]. As a result, dephosphorylation of p38MAPK by Wip1 was blocked as demonstrated by the increased level of phosphorylated p38MAPK, especially in the cRb\(^{-/-}\)/Ras\(^{V12}\) group (Figure 5A). This biochemical outcome correlates with the positive staining observed in SA-β-Galactosidase assays (Figure 5B). In addition, proliferation rates observed in cRb\(^{loxP/loxP}\)/Ras\(^{V12}\) and cRb\(^{-/-}\)/Ras\(^{V12}\) treated groups were significantly lower that the same cells without treatments (Figure S4), confirming previous reports where Pum1\(^{−/−}\) MEFs showed reduced proliferation rate with features of early senescence [52].

Discussion

Collectively, our results show that astrocytes expressing oncogenic Ras display a strong proliferation in the absence of senescence, facilitating their transformation into tumoral cells both in vitro and in vivo. This observation has not been established in other lineages, where OIS blocks tumor progression [17,48]. In addition to that, the activation of DNA damage checkpoint response detected in these cells raises some questions about the kind of relationship that DDR holds with OIS. Although it has been reported that OIS is a consequence of the activation of DDR [19–22] we observed that in astrocytes DDR activation does not necessary lead to senescence. At the same time, the pRb requirement for Ras-mediated transformation [53] was not found in our model. Our data indicate that HRas\(^{V12}\) is able to cooperate with Rb loss in the tumor malignization. This cooperation between Ras and Rb loss opposes the conception that pRb is an essential mediator that links Ras-dependent mitogenic signaling to cell cycle regulation [54].

Given that p38MAPK-deficient cells are sensitized to HRas\(^{V12}\)-induced transformation [25] and although the inactivation of Wip1 is related to the inhibition of tumorigenesis [55], our data point out that the cooperation between Ras and loss of Rb could be due to the increase of Wip1 and consequently p38MAPK inactivation. In this way, Rb loss in HRas\(^{V12}\)-expressing astrocytes confers a double advantage. On one hand, Rb absence increases the astrocytes proliferative rate but on the other hand, in a Rb knock-out context, E2F-1 is activated and up-regulates both DNA damage response in an DNA damage-independent manner, favoring repair mechanisms, and Wip1 [30], leading to an inactivation of p38MAPK and thus increasing cellular transformation. All of this may explain the low latency of cRb\(^{-/-}\)/Ras\(^{V12}\) tumors versus cRb\(^{loxP/loxP}\)/Ras\(^{V12}\) tumors and the high Wip1 expression observed in high-grade human gliomas. Interestingly enough, Wip1 chemical inhibition in cRb\(^{-/-}\)/Ras\(^{V12}\) astrocytes leads to a significant fall in the proliferative rate of these cells, which eventually enter senescence as opposed to cells where Wip1
remains unaffected. Lately, several authors have proposed the use of selective therapeutic inhibitors targeting Wip1 as a promising treatment for different types of cancer [56–58]. This study sheds new lights on the possible mechanisms behind the progression from preneoplastic lesions to malignant tumors (Figure 6), and according to our glioma model identifies Wip1 as a potential druggable target for new therapeutic approaches for a tumor whose bad prognosis has not significantly changed over the past two decades.

Materials and Methods

Cell culture and SA-β-Galactosidase assay

Astrocytes were generated from cRb<sup>loxP/loxP</sup> neonatal mice at day 3. The care and use of all experimental animals was in accordance with institutional guidelines. Cells were maintained in Dulbecco modified Eagle medium (Sigma) with 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin (GIBCO-Invitrogen). For introduction of an activated Ras allele and Rb loss into astrocytes, Phoenix-Eco packaging cells (a gift from G.P. Nolan) were transfected with pBABE, pBABE-HRas<sup>V12</sup>, PIG-puro and PIG-CRE retroviral plasmids (a gift from P.P. Pandolfi). SA-β-galactosidase activity was assessed with the Senescence β-Galactosidase Staining Kit (Cell Signaling).

Immunoblot

Cultures were washed twice in ice-cold PBS, lyed in ice-cold RIPA buffer (1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml PMSF, 40 μg of aprotinin/ml, 100 mM orthovanadate). Analysis of protein levels was carried out by immunoblot analysis using polyclonal antibodies (Abs) against p53 (CM5; Novocastra), p-p53 ser15 (9284; Cell Signaling), p19ARF (ab80; Abcam), p38 (C-20; Santa Cruz), p-p38 (Thr180/Tyr182) (sc-17852; Santa Cruz), p16 (M-156; Santa Cruz), p107 (C-18; Santa Cruz), p-H2AX Ser139 (07-164 Upstate) and WIP-1 (H-300; Santa Cruz) and the monoclonal antibodies pan-Ras (Ab-3; Calbiochem), pan-Ras-V<sup>12</sup> (Ab-1; Calbiochem), anti-α-Tubulin (T5168; Sigma) and Rb (554136; BD). Densito-
metric analyses were performed using UN-SCAN-IT software (Silk Scientific, UT, USA).

Immunohistochemistry

Twenty cases of human astrocytomas, ten low-grade (grades I–II) and ten high-grade (grade III–IV), were retrieved from the files of the Pathology Department of the Clinical University Hospital, Santiago de Compostela, Spain. The tumors had been diagnosed according to standard criteria from the last WHO classification. Two tissue microarrays (TMAs) were constructed from these cases using a Tissue Arrayer device (Beecher Instruments, Sun Prairie, WI). Two selected 1.5-mm diameter cylinders from two represent-

Figure 4. Rb loss enhances DNA damage response (DDR) induced by oncogenic Ras and reduces the p-p38MAPK levels by upregulation of Wip1. a, HRasV\(^{12}\) is able to induce DDR markers expression, such as p16\(^{INK4a}\), p21\(^{Cip1}\) and p19\(^{ARF}\), p53 and p53\(^{ser15}\) and \(\gamma\)-H2AX\(^{ser139}\). Rb loss, in the presence of oncogenic Ras, increases this response. Immunoblot analysis was performed on astrocytes lysates prepared at day 6 after co-infection and selection with puromycin. b, Immunoblot analysis of p-p38MAPK and Wip1 levels was performed on cell lysates prepared at day 5 from co-infection and selection with puromycin. Densitometric analysis (in relative densitometric units) of Wip1 and p-p38MAPK protein levels. c, TMA analysis of Wip1 expression in glioma clinical samples. Representative pictures of samples are shown. The table shows median values. Wip1 immunoreactivity intensity was assigned according to the following scale: NA, non-assessable cases; –, less than 10% of neoplastic cells displayed immunoreactivity; +, 11–29% of neoplastic cells displayed immunoreactivity; ++, 30% or greater percentage of neoplastic cells displayed immunoreactivity. Phospho-histone H3 was used as a proliferation marker. Scale bars, 50 \(\mu m\).

doi:10.1371/journal.pone.0003632.g004
tative areas histologically reviewed were included in each case. Internal and external appropriate controls were included in each TMA. TMA blocks were sectioned to produce 4-μm sections. Immunohistochemistry was performed using a universal second antibody kit that used a peroxidase-conjugated labeled-dextran polymer (Envision Plus, Dako, Denmark). The following primary antibodies were used: Wip1 (polyclonal, Santa Cruz Biotechnology, USA), phospho-histone H3 (polyclonal, Cell Signaling Technology) and p-p38 (polyclonal, Santa Cruz Biotechnology). Prior to immunostaining, antigen retrieval was performed by the sections in buffer by 20 min (Tris-EDTA pH 9 for Wip1 and p-p38, citrate buffer pH 6 for H3). Overnight incubation at 4°C was performed with every antibody.

Metaphase chromosome preparation and FISH
Metaphase spreads were prepared from exponentially growing cells after treatment with colcemid (0.1 μg/ml) for 7 hr. Cells were incubated in hypotonic buffer (0.05 M KCl, 0.0034 M trisodium citrate) for 20 min at 37°C and fixed 75% methanol, 25% acetic acid. Cells were then spotted onto microscope slides and stained with 2% Wright in Gurr buffer (pH 7.0). Metaphase chromosomes were scored using a Leica 2005 microscope under a 100× oil objective lens. At least 50 metaphases were analyzed from three independent experiments. TFISH was performed on unstained metaphase chromosomes using a Cy3-labeled peptide nucleic acid probe. For T-FISH, both the DNA probe and the slides were heat denatured (80°C for 5 min) and hybridized at 37°C for 2 hr according to the manufacturer’s specifications (Dako Cytomation). Slides were counterstained with DAPI, and the images were captured using a Leica 2005 microscope equipped with the software program by Leica 4000.

Wip1 inhibition treatment

Figure 5. Wip1 inhibition enables senescence in cRb<sup>−/−</sup>/Ras<sup>V12</sup> astrocytes. a, All the experimental groups were treated with the Wip1 chemical inhibitors CCT007093 and Arsenic Trioxide (ATO). Levels of p-p38MAPK were assessed by Western blot analysis as a readout of Wip1 phosphatase activity inhibition. b, SA-β-galactosidase assays in all groups (without treatment, ATO treatment, CCT007093 treatment). The y-axis represents the percentage of positive cells (mean and s.d.). doi:10.1371/journal.pone.0003632.g005

Figure 6. DDR is modulated by Rb loss switching premalignant lesion to cancer.

doi:10.1371/journal.pone.0003632.g006
Cornwall, UK) or Arsenic Trioxide (Sigma) in the second day upon infection at a concentration of 25 μM and 10 μM, respectively. Subsequent cell fixation and crystal violet staining were carried out in the indicated days.

Supporting Information

Figure S1 Telomere fluorescence in situ hybridization (T-FISH) of metaphase spreads. Merged images of DAPI (blue) and telomeric probe (red). The selected regions of metaphase spreads from mouse astrocytes infected with HRASV12 are magnified to show centromere fragments (CF) and Robertsonian centromeric fusion (Rob), indicated by arrows.

Found at: doi:10.1371/journal.pone.0003632.s001 (3.00 MB TIF)

Figure S2 Acute deletion of Rb in astrocytes and analysis of pRb and p107 levels. Immunoblot analysis of proliferating cRblocP/loxP astrocytes after infection at day 1 and 6 post-selection with puromycin. pRb was no longer detectable at day 1 after selection. The pRb family member p107 was significantly affected by loss of pRb. Compensation of pRb loss by p107 presence is already present at day 1.

Found at: doi:10.1371/journal.pone.0003632.s002 (3.00 MB TIF)

Figure S3 Acute deletion of Rb in astrocytes and the effect on Wip1 and pp38 levels. Immunoblot analysis of proliferating cRblocP/loxP astrocytes after infection at day 1 and 6 post-selection with puromycin. The lower level of pp38 is shown after 7 days but not at day 1 after selection.

References

1. Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(3): 255–268.
2. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A (1997) Proliferation of human malignant astrocytomas is dependent on ras activation. Oncogene 15(23): 2755–2765.
3. Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A (1999) NORMoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by ras. J Natl Cancer Inst 81(1): 118–124.
4. Rajasekhar V, Viale A, Soeci ND, Wiedmann M, Hu X, et al. (2003) Oncogenic ras and akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12(4): 809–840.
5. Hu X, Pandalippi PP, Li Y, Kouchner JA, Rosenhamb M, et al. (2005) mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7(4): 356–368.
6. Ding H, Renzari L, Shamon P, Wou X, Lau N, et al. (2001) Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61(9): 3836–3836.
7. Shannon P, Sabha N, Lau N, Kamnasaran D, Gutmann DH, et al. (2005) Pathological and molecular progression of astrocytomas in a GFAP-12 V-hras mouse astrocytoma model. Am J Pathol 167(3): 859–867.
8. Rich JN, Guo C, McLendon RE, Bigner DG, Wang X-F, et al. (2001) A Genetically Tractable Model of Human Glioma Formation. Cancer Res 61: 3356–3360.
9. Jen J, Harper J, Bigner SH, Bigner DG, Papadopoulou N, et al. (1994) Deletion of p15 and p16 genes in brain tumors. Cancer Res 54(24): 6353–6358.
10. Schmid EF, Ichimura K, Reifenberger G, Collins VP (1994) Cdkn2 (p16/MTS1) gene deletion or cdk4 amplification occurs in the majority of gliomas. Cancer Res 54(24): 6321–6324.
11. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83(6): 993–1000.
12. He J, Allen JR, Collins VP, Alabani-Turner MJ, Godbout R, et al. (1994) Cdk4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cells. Cancer Res 54(22): 5804–5807.
13. He J, Olson JJ, James CD (1993) Lack of p16(INK4) or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 53(22): 4833–4836.
14. Ichimura K, Schmid EF, Goike HM, Collins VP (1996) Human glioblastomas with no alterations of the Cdkn2a (p16INK4A, MTS1) and Cdk4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13(3): 1065–1073.
15. Rathiore A, Kamarajan P, Mathur M, Sinha S, Sarkar C (1999) Simultaneous Alterations of Retinoblastoma and p53 Protein Expression in Astrocytic Tumors. Pathol Oncol Res 5(1): 21–27.
16. Brookes S, Rowe J, Rius M, Llanos S, Clark PA, et al. (2002) INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 21(12): 2936–2945.
17. Serrano M, Liu AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 83(5): 593–602.
18. Collado M, Gil J, Efeyan A, Guerra C, Schulmacher AJ, et al. (2005) Tumour biology: Senescence in premalignant tumours. Nature 436(7051): 642.
19. Barokova J, Horejzi Z, Koel K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7055): 864–870.
20. Gorgoulis VG, Vasilou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human preneoplastic lesions. Nature 434(7055): 907–913.
21. Di Meco R, Fumagalli M, Cicalèse A, Piccinin S, Gasparini P, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119): 638–642.
22. Barokova J, Rzezañ K, Liontos M, Karakaidos P, Kletsas D, et al. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119): 635–637.
23. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, et al. (2002) Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6/p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22(16): 3839–3843.
24. Bulavin DV, Kováčky O, Hollander MC, Fornace AJ Jr (2005) Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 25(11): 3835–3847.
25. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, et al. (2007) p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11(2): 191–203.
26. Holland EC, Hively WP, Gallo V, Varmus HE (1998) Oncogene-induced senescence in premalignant tumours. Nature 434(7051): 638–642.
27. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, et al. (2002) Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6/p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22(16): 3839–3843.
28. Bulavin DV, Kováčky O, Hollander MC, Fornace AJ Jr (2005) Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 25(11): 3835–3847.
29. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, et al. (2007) p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11(2): 191–203.
30. Holland EC, Hively WP, Gallo V, Varmus HE, (1998) Modeling mutations in the MEK-extracellular signal-regulated kinase and MKK3/6/p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22(16): 3839–3843.
31. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) Modeling mutations in the MEK-extracellular signal-regulated kinase and MKK3/6/p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22(16): 3839–3843.
32. Holland EC, Hively WP, DePinho RA, Varmus HE, (1998) Modeling mutations in the MEK-extracellular signal-regulated kinase and MKK3/6/p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 22(16): 3839–3843.
29. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, et al. (2004) E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2(4): 203–214.

30. Hershko T, Korotayev K, Polakger S, Ginsburg D (2006) E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J Biol Chem 281(42): 31309–31316.

31. Holland EC (2003) Gliomagenesis: Genetic alterations and mouse models. Nat Rev Genet 2(2): 120–129.

32. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Der CJ, et al. (2000) Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of rb in the external granular layer cells of the cerebellum. Genes Dev 14(8): 994–1004.

33. Peepo DS, Dannenberg JH, Domsa S, te Riele H, Bernards R (2001) Escape from premature senescence is not sufficient for oncogenic transformation by ras. Nat Cell Biol 3(2): 198–203.

34. Lee KY, Ladha MH, McMahon C, Ewen ME (1999) The Retinoblastoma Protein Is Linked to the Activation of Ras. Mol Cell Biol 19(11): 7724–7732.

35. Sathyan KM, Nalinakumari KR, Kannan S (2007) H-Ras mutation modulates MAPK-p53 signaling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 444(7119): 633–637.

36. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T (2003) Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424(6945): 223–228.

37. Reinhardt HC, Aslanian AS, Lees YA, Yaffe MB (2000) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell 1(2): 175–189.

38. Chen G, Hizumi M, Han J, Stacey DW (2000) The p38 pathway provides negative feedback for ras proliferative signaling. J Biol Chem 275(50): 38973–38980.

39. Sun P, Yoshizuka N, New L, Moser BA, Li Y, et al. (2007) PRAK is essential for ras-induced senescence and tumor suppression. Cell 129(2): 295–308.

40. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, et al. (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 94(12): 6048–6053.

41. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, et al. (2004) The superoxide-generating oxidase Nox1 is functionally required for ras oncogene transformation. Cancer Res 64(10): 3500–3505.

42. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31(2): 210–215.

43. Williams JP, Stewart T, Li B, Mulloy R, Dimova D, et al. (2006) The retinoblastoma protein is required for ras-induced oncogenic transformation. Mol Cell Biol 26(4): 1170–1182.

44. Takekawa M, Adachi M, Nakahata A, Nakayama I, Ichikashi T, et al. (2006) p38-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19(23): 6517–6526.

45. Bulavin DV, Phillips C, Rooman B, Timofeev O, Donehower LA, et al. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(arf) pathway. Nat Genet 36(4): 343–350.

46. Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, et al. (2008) A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Nature 444(7120): 1507–1510.

47. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell 1(2): 175–189.

48. Chen G, Hizumi M, Han J, Stacey DW (2000) The p38 pathway provides negative feedback for ras proliferative signaling. J Biol Chem 275(50): 38973–38980.

49. Sun P, Yoshizuka N, New L, Moser BA, Li Y, et al. (2007) PRAK is essential for ras-induced senescence and tumor suppression. Cell 129(2): 295–308.

50. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, et al. (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 94(12): 6048–6053.

51. Takekawa M, Adachi M, Nakahata A, Nakayama I, Ichikashi T, et al. (2006) p38-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19(23): 6517–6526.

52. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31(2): 210–215.

53. Williams JP, Stewart T, Li B, Mulloy R, Dimova D, et al. (2006) The retinoblastoma protein is required for ras-induced oncogenic transformation. Mol Cell Biol 26(4): 1170–1182.

54. Takekawa M, Adachi M, Nakahata A, Nakayama I, Ichikashi T, et al. (2006) p38-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19(23): 6517–6526.

55. Bulavin DV, Phillips C, Rooman B, Timofeev O, Donehower LA, et al. (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(arf) pathway. Nat Genet 36(4): 343–350.

56. Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson GW, et al. (2006) Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry 45(44): 13193–13202.

57. Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, et al. (2008) A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27(8): 1036–1044.

58. Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, et al. (2008) Arsenic Trioxide Augments Chk2/p53-mediated Apoptosis by Inhibiting Oncogenic Wip1 Phosphatase. J Biol Chem 283(27): 18969–18979.